Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED)
Therapeutic Advances in Medical Oncology · 2025-01 · 17
DOI: 10.1177/17588359251344010 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 16.06.2025. Verfasst von Masashi Ishihara und 49 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly Japan.
Abstract (Originalsprache)
Background
EGFR L858R mutation is associated with poorer efficacy of EGFR-tyrosine kinase inhibitors (TKIs) than EGFR Ex19del in patients with non-small cell lung cancer (NSCLC). However, ramucirumab (RAM) + erlotinib (ERL) therapy exhibited comparable efficacy between patients with L858R mutation and Ex19del mutation (median progression-free survival (PFS): 19.6 vs 19.4 months) in the RELAY study, with favorable PFS for both gene mutations at 19.4 months in the Japanese subset. Meanwhile, the FLAURA study revealed shorter PFS with osimertinib (OSI) for L858R mutation than Ex19del mutation, with poorer PFS in the Japanese subset than in the overall population. The treatment discontinuation rates of RAM + ERL and OSI in Japanese patients were 18% and 29%, respectively. Consequently, RAM + ERL may exhibit superior efficacy and safety in Japanese patients with the L858R mutation.
Objectives
To evaluate the therapeutic efficacy and safety of RAM + ERL as a first-line treatment for advanced or recurrent NSCLC harboring the L858R mutation in Japanese patients.
Design
A multicenter, noninterventional, retrospective cohort study. Methods and analysis: This study will involve patients with advanced or recurrent NSCLC (ECOG PS score 0–2) with L858R mutation who received RAM + ERL between November 1, 2020 and August 31, 2023, with the planned sample size of 200 patients. The primary endpoint is time to treatment failure, and the secondary endpoints are overall survival, PFS, PFS2, time to discontinuation of any EGFR-TKI, time to failure of strategy, objective response rate, disease control rate, and safety. Exploratory endpoints are effects of ERL and RAM on PD-L1 expression and neutrophil-to-lymphocyte ratio.
Discussion
To the best of our knowledge, this is the first retrospective study focusing on L858R mutations associated with the RELAY regimen, providing the corresponding real-world data.
Trial registration
UMIN Clinical Trials Registry identifier: UMIN000052047.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.
- Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
- Department of Respiratory Medicine, Juntendo University Urayasu Hospital, Chiba, Japan.
- Department of Thoracic Oncology, Kansai Medical University, Osaka, Japan.
- Department of Respiratory Medicine, Aomori Prefectural Central Hospital, Aomori, Japan.
- Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Hyogo, Japan.
ORCID-Profile: Masashi Ishihara, Yoshiki Negi
Förderung
- Eli Lilly Japan
Zitieren
APA
Ishihara, M., Kawamura, T., Namba, Y., Takeyasu, Y., Hasegawa, Y., Sato, Y., Negi, Y., Oba, T., Sumi, T., Hirata, H., Funabashi, H., Oya, Y., Kikuchi, H., Katsurada, N., Nakatani, T., Tanimura, K., Nakagawa, T., Takeda, N., Asami, T., …, & Seki, N. (2025). Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED). Therapeutic Advances in Medical Oncology, 17. https://doi.org/10.1177/17588359251344010
Vancouver
Ishihara M, Kawamura T, Namba Y, Takeyasu Y, Hasegawa Y, Sato Y, et al. Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED). Therapeutic Advances in Medical Oncology. 2025;17. doi:10.1177/17588359251344010
BibTeX
@article{Ishihara2025,
author = {Ishihara, Masashi and Kawamura, Takahisa and Namba, Yukiko and Takeyasu, Yuki and Hasegawa, Yukihiro and Sato, Yuki and Negi, Yoshiki and Oba, Tomohiro and Sumi, Toshiyuki and Hirata, Hirokuni and Funabashi, Hidemitsu and Oya, Yuko and Kikuchi, Hajime and Katsurada, Naoko and Nakatani, Takeshi and Tanimura, Keiko and Nakagawa, Taku and Takeda, Naoya and Asami, Takahiro and Honjo, Osamu and Nagashima, Hiromi and Yamaura, Takumi and Hata, Norihiko and Kitazono, Miyako and Nishioka, Naoya and Tamiya, Akihiro and Sakamori, Yuichi and Shigaki, Ryota and Kaira, Kyoichi and Honda, Ryoichi and Matsui, Takashi and Suzuki, Eriko and Ito, Kentaro and Otsuka, Kojiro and Takase, Naoto and Murakami, Yusuke and Matsuno, Kazuhiko and Inoue, Sumito and Kisohara, Akira and Kusumoto, Sojiro and Aoshima, Hiroe and Kakizaki, Yumiko and Kubo, Akihito and Hata, Akito and Ishikawa, Nobuhisa and Hamai, Kosuke and Kanaji, Nobuhiro and Misumi, Toshihiro and Matsutani, Noriyuki and Seki, Nobuhiko},
title = {Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED)},
journal = {Therapeutic Advances in Medical Oncology},
year = {2025},
volume = {17},
doi = {10.1177/17588359251344010}
}
EUVIMED